Castle Biosciences, Inc.

Contributing Author

Recent Articles by Castle Biosciences, Inc.

May-29	New Data at ASCO 2025 Affirms DecisionDx-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes CSTL GlobeNewswire
May-21	Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference CSTL GlobeNewswire
May-09	Real-World Study Confirms Long-Term Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result CSTL GlobeNewswire
May-07	Castle Biosciences Celebrates Skin Cancer Awareness Month CSTL GlobeNewswire
May-05	Castle Biosciences Reports First Quarter 2025 Results CSTL GlobeNewswire
May-05	Castle Biosciences to Acquire Previse CSTL GlobeNewswire
May-02	New Data at DDW 2025 Further Demonstrates the TissueCypher Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer CSTL GlobeNewswire